drugset

drugset / Trial / NCT02241434

Stem Cell Therapy in Duchenne Muscular Dystrophy

NCT02241434 ↗

Phase 1 Withdrawn Neurogen Brain and Spine Institute

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to study the effect of stem cell therapy in patients with Duchenne Muscular Dystrophy.

Timeline

Start: 2009-01
Primary completion: 2016-01
Completion: 2016-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Stem Cell	Cell therapy	—	Intrathecal

Indications